Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 18 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Keyword is Receptors, Estrogen  [Clear All Filters]
2018
Leszek, J., Trypka E., Koutsouraki E., Michmizos D., Yarla N. Sastry, Tarasov V. V., et al. (2018).  Late-life Depression and Alzheimer Disease: A Potential Synergy of the Underlying Mechanisms.. Curr Med Chem. 25(39), 5389-5394.
2014
Lakis, S., Kotoula V., Eleftheraki A. G., Batistatou A., Bobos M., Koletsa T., et al. (2014).  The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.. Breast. 23(3), 234-43.
Toesca, A., Botteri E., Lazzeroni M., Vila J., Manika A., Ballardini B., et al. (2014).  Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence.. Breast. 23(6), 829-35.
2013
Batistatou, A., Televantou D., Bobos M., Eleftheraki A. G., Kouvaras E., Chrisafi S., et al. (2013).  Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.. Anticancer Res. 33(5), 2139-45.
2012
Stevens, K. N., Fredericksen Z., Vachon C. M., Wang X., Margolin S., Lindblom A., et al. (2012).  19p13.1 is a triple-negative-specific breast cancer susceptibility locus.. Cancer Res. 72(7), 1795-803.
Fountzilas, G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., et al. (2012).  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.. PLoS One. 7(6), e37946.
Fountzilas, G., Valavanis C., Kotoula V., Eleftheraki A. G., Kalogeras K. T., Tzaida O., et al. (2012).  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.. J Transl Med. 10, 10.
Fostira, F., Tsitlaidou M., Papadimitriou C., Pertesi M., Timotheadou E., Stavropoulou A. V., et al. (2012).  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.. Breast Cancer Res Treat. 134(1), 353-62.
Skarlos, P., Christodoulou C., Kalogeras K. T., Eleftheraki A. G., Bobos M., Batistatou A., et al. (2012).  Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.. Cancer Chemother Pharmacol. 69(2), 533-46.
2011
Stevens, K. N., Vachon C. M., Lee A. M., Slager S., Lesnick T., Olswold C., et al. (2011).  Common breast cancer susceptibility loci are associated with triple-negative breast cancer.. Cancer Res. 71(19), 6240-9.
Haiman, C. A., Chen G. K., Vachon C. M., Canzian F., Dunning A., Millikan R. C., et al. (2011).  A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.. Nat Genet. 43(12), 1210-4.
Razis, E., Bobos M., Kotoula V., Eleftheraki A. G., Kalofonos H. P., Pavlakis K., et al. (2011).  Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.. Breast Cancer Res Treat. 128(2), 447-56.
2010
Ihnen, M., Wirtz R. M., Kalogeras K. T., Milde-Langosch K., Schmidt M., Witzel I., et al. (2010).  Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.. Br J Cancer. 103(7), 1048-56.
Koletsa, T., Kotoula V., Karayannopoulou G., Nenopoulou E., Karkavelas G., Papadimitriou C. S., et al. (2010).  EGFR expression and activation are common in HER2 positive and triple-negative breast tumours.. Histol Histopathol. 25(9), 1171-9.
Antoniou, A. C., Wang X., Fredericksen Z. S., McGuffog L., Tarrell R., Sinilnikova O. M., et al. (2010).  A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.. Nat Genet. 42(10), 885-92.
Gogas, H., Pectasides D., Kostopoulos I., Lianos E., Skarlos D., Papaxoinis G., et al. (2010).  Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.. Clin Breast Cancer. 10(3), 230-7.
2009
Pentheroudakis, G., Kalogeras K. T., Wirtz R. M., Grimani I., Zografos G., Gogas H., et al. (2009).  Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.. Breast Cancer Res Treat. 116(1), 131-43.
Kyrou, D., Kolibianakis E. M., Venetis C. A., Miliaras D., Theodoridis T., Tzevelekis F., et al. (2009).  Steroid receptor expression in human endometrium during the follicular phase of stimulated cycles.. Hum Reprod. 24(11), 2931-5.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές